menu
Scientific Poster

Analytical Validation of Illumina’s TruSight Oncology 500 ctDNA Assay

AACR 2020 Poster

Minimally invasive liquid biopsy tests are emerging as complements in the clinical management of cancer patients. The ability to accurately detect low frequency somatic mutations, as well as composite biomarkers, such as tumor mutational burden, or TMB, and microsatellite instability, or MSI, from a single plasma sample using a broad based NGS panel is of high value. In this poster, we describe the performance of Illumina’s TruSight Oncology 500 ctDNA assay for detection of low frequency SNVs and Indels, and TMB analysis. Download poster to learn more.

Related Services:

Clinical Trial Genomics Laboratory Services

A tour of our genomics laboratory

Non-invasive Detection of Immunotherapy Biomarkers using TruSight Oncology 500 (TSO500)

TSO500 Plasma Assay

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Genomics Laboratory Sequencing Capabilities

Global genomic testing services to support drug discovery, precision medicine, and clinical development

Read More